Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization

Hyun Jung Choi, Na Eun Kim, Jayoung Kim, Sunho An, Seung Hee Yang, Jimin Ha, Sunghee Cho, Il Kwon, Young Dae Kim, Hyo Suk Nam, Ji Hoe Heo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dabigatran etexilate (DE), a new oral anti-coagulant, is a direct thrombin inhibitor. Clinical trials showed the favorable benefit-to-risk profile of DE compared to warfarin for the prevention of ischemic stroke in patients with atrial fibrillation. Remarkably, patients treated with dabigatran showed reduced rates of intracerebral hemorrhage compared to warfarin. As the breakdown of endothelial barrier integrity is associated with hemorrhagic events and as thrombin increases endothelial permeability, we hypothesized that dabigatran preserves the endothelial barrier by inhibiting thrombin-induced permeability. We assessed leakage of fluorescein isothiocyanate (FITC)-dextran through the endothelial monolayer and measured trans-endothelial electrical resistance of the endothelial monolayer after treatment of thrombin or thrombin pre-incubated with dabigatran. Thrombin increased the permeability of endothelial cells. Dabigatran effectively blocked the ability of thrombin to increase permeability. Dabigatran inhibited the formation of actin stress fibers induced by thrombin and inhibited consequent destabilization of junctional protein complexes and intercellular gap formation. The interaction of thrombin with protease activated receptor-1 activates the Rho A guanosine triphosphate (GTP)ase-myosin light chain (MLC) phosphorylation signaling axis, leading to actin cytoskeleton changes. This signaling pathway was effectively inhibited by dabigatran in endothelial cells. Consistently, the number of phosphorylated MLC-positive cells was significantly decreased in ischemic tissue of rat brains. These results indicate dabigatran blocks the ability of thrombin to induce vascular permeability and the resulting underlying signaling cascade in endothelial cells. Our findings provide evidence that dabigatran may confer a lower risk of intracerebral hemorrhage by preserving endothelial barrier integrity.

Original languageEnglish
Pages (from-to)165-171
Number of pages7
JournalThrombosis Research
Volume167
DOIs
Publication statusPublished - 2018 Jul

Fingerprint

Cytoskeleton
Thrombin
Permeability
Myosin Light Chains
Endothelial Cells
Cerebral Hemorrhage
Warfarin
Dabigatran
PAR-1 Receptor
Coagulants
Stress Fibers
Antithrombins
Capillary Permeability
Guanosine Triphosphate
Electric Impedance
Actin Cytoskeleton
Atrial Fibrillation
Actins
Stroke
Phosphorylation

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Choi, Hyun Jung ; Kim, Na Eun ; Kim, Jayoung ; An, Sunho ; Yang, Seung Hee ; Ha, Jimin ; Cho, Sunghee ; Kwon, Il ; Kim, Young Dae ; Nam, Hyo Suk ; Heo, Ji Hoe. / Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization. In: Thrombosis Research. 2018 ; Vol. 167. pp. 165-171.
@article{345583ac88d24d1f97ccd8363edca97a,
title = "Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization",
abstract = "Dabigatran etexilate (DE), a new oral anti-coagulant, is a direct thrombin inhibitor. Clinical trials showed the favorable benefit-to-risk profile of DE compared to warfarin for the prevention of ischemic stroke in patients with atrial fibrillation. Remarkably, patients treated with dabigatran showed reduced rates of intracerebral hemorrhage compared to warfarin. As the breakdown of endothelial barrier integrity is associated with hemorrhagic events and as thrombin increases endothelial permeability, we hypothesized that dabigatran preserves the endothelial barrier by inhibiting thrombin-induced permeability. We assessed leakage of fluorescein isothiocyanate (FITC)-dextran through the endothelial monolayer and measured trans-endothelial electrical resistance of the endothelial monolayer after treatment of thrombin or thrombin pre-incubated with dabigatran. Thrombin increased the permeability of endothelial cells. Dabigatran effectively blocked the ability of thrombin to increase permeability. Dabigatran inhibited the formation of actin stress fibers induced by thrombin and inhibited consequent destabilization of junctional protein complexes and intercellular gap formation. The interaction of thrombin with protease activated receptor-1 activates the Rho A guanosine triphosphate (GTP)ase-myosin light chain (MLC) phosphorylation signaling axis, leading to actin cytoskeleton changes. This signaling pathway was effectively inhibited by dabigatran in endothelial cells. Consistently, the number of phosphorylated MLC-positive cells was significantly decreased in ischemic tissue of rat brains. These results indicate dabigatran blocks the ability of thrombin to induce vascular permeability and the resulting underlying signaling cascade in endothelial cells. Our findings provide evidence that dabigatran may confer a lower risk of intracerebral hemorrhage by preserving endothelial barrier integrity.",
author = "Choi, {Hyun Jung} and Kim, {Na Eun} and Jayoung Kim and Sunho An and Yang, {Seung Hee} and Jimin Ha and Sunghee Cho and Il Kwon and Kim, {Young Dae} and Nam, {Hyo Suk} and Heo, {Ji Hoe}",
year = "2018",
month = "7",
doi = "10.1016/j.thromres.2018.04.019",
language = "English",
volume = "167",
pages = "165--171",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",

}

Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization. / Choi, Hyun Jung; Kim, Na Eun; Kim, Jayoung; An, Sunho; Yang, Seung Hee; Ha, Jimin; Cho, Sunghee; Kwon, Il; Kim, Young Dae; Nam, Hyo Suk; Heo, Ji Hoe.

In: Thrombosis Research, Vol. 167, 07.2018, p. 165-171.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization

AU - Choi, Hyun Jung

AU - Kim, Na Eun

AU - Kim, Jayoung

AU - An, Sunho

AU - Yang, Seung Hee

AU - Ha, Jimin

AU - Cho, Sunghee

AU - Kwon, Il

AU - Kim, Young Dae

AU - Nam, Hyo Suk

AU - Heo, Ji Hoe

PY - 2018/7

Y1 - 2018/7

N2 - Dabigatran etexilate (DE), a new oral anti-coagulant, is a direct thrombin inhibitor. Clinical trials showed the favorable benefit-to-risk profile of DE compared to warfarin for the prevention of ischemic stroke in patients with atrial fibrillation. Remarkably, patients treated with dabigatran showed reduced rates of intracerebral hemorrhage compared to warfarin. As the breakdown of endothelial barrier integrity is associated with hemorrhagic events and as thrombin increases endothelial permeability, we hypothesized that dabigatran preserves the endothelial barrier by inhibiting thrombin-induced permeability. We assessed leakage of fluorescein isothiocyanate (FITC)-dextran through the endothelial monolayer and measured trans-endothelial electrical resistance of the endothelial monolayer after treatment of thrombin or thrombin pre-incubated with dabigatran. Thrombin increased the permeability of endothelial cells. Dabigatran effectively blocked the ability of thrombin to increase permeability. Dabigatran inhibited the formation of actin stress fibers induced by thrombin and inhibited consequent destabilization of junctional protein complexes and intercellular gap formation. The interaction of thrombin with protease activated receptor-1 activates the Rho A guanosine triphosphate (GTP)ase-myosin light chain (MLC) phosphorylation signaling axis, leading to actin cytoskeleton changes. This signaling pathway was effectively inhibited by dabigatran in endothelial cells. Consistently, the number of phosphorylated MLC-positive cells was significantly decreased in ischemic tissue of rat brains. These results indicate dabigatran blocks the ability of thrombin to induce vascular permeability and the resulting underlying signaling cascade in endothelial cells. Our findings provide evidence that dabigatran may confer a lower risk of intracerebral hemorrhage by preserving endothelial barrier integrity.

AB - Dabigatran etexilate (DE), a new oral anti-coagulant, is a direct thrombin inhibitor. Clinical trials showed the favorable benefit-to-risk profile of DE compared to warfarin for the prevention of ischemic stroke in patients with atrial fibrillation. Remarkably, patients treated with dabigatran showed reduced rates of intracerebral hemorrhage compared to warfarin. As the breakdown of endothelial barrier integrity is associated with hemorrhagic events and as thrombin increases endothelial permeability, we hypothesized that dabigatran preserves the endothelial barrier by inhibiting thrombin-induced permeability. We assessed leakage of fluorescein isothiocyanate (FITC)-dextran through the endothelial monolayer and measured trans-endothelial electrical resistance of the endothelial monolayer after treatment of thrombin or thrombin pre-incubated with dabigatran. Thrombin increased the permeability of endothelial cells. Dabigatran effectively blocked the ability of thrombin to increase permeability. Dabigatran inhibited the formation of actin stress fibers induced by thrombin and inhibited consequent destabilization of junctional protein complexes and intercellular gap formation. The interaction of thrombin with protease activated receptor-1 activates the Rho A guanosine triphosphate (GTP)ase-myosin light chain (MLC) phosphorylation signaling axis, leading to actin cytoskeleton changes. This signaling pathway was effectively inhibited by dabigatran in endothelial cells. Consistently, the number of phosphorylated MLC-positive cells was significantly decreased in ischemic tissue of rat brains. These results indicate dabigatran blocks the ability of thrombin to induce vascular permeability and the resulting underlying signaling cascade in endothelial cells. Our findings provide evidence that dabigatran may confer a lower risk of intracerebral hemorrhage by preserving endothelial barrier integrity.

UR - http://www.scopus.com/inward/record.url?scp=85046723952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046723952&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2018.04.019

DO - 10.1016/j.thromres.2018.04.019

M3 - Article

AN - SCOPUS:85046723952

VL - 167

SP - 165

EP - 171

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -